Reversible acceleration of disease progression following cyclosporin A treatment in a patient with myelodysplastic syndrome

International Journal of Hematology

Volumn 75, Issue 3, 2002, Pages 302-304

  Itoh, Mitsuru ^a   Yago, Kazuhiro ^a   Shimada, Hideto ^a   Tohyama, Kaoru ^b  

^a SHIZUOKA GENERAL HOSPITAL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Cyclosporin A; Disease progression; Myelodysplastic syndrome

Indexed keywords

ANTILEUKEMIC AGENT; CYCLOSPORIN A; LACTATE DEHYDROGENASE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; BLOOD EXAMINATION; BONE MARROW; CASE REPORT; CHROMOSOME ANALYSIS; DISEASE COURSE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MYELODYSPLASTIC SYNDROME; PHYSICAL EXAMINATION; TREATMENT WITHDRAWAL; ASIAN; BLOOD; BLOOD CELL COUNT; FEMALE; JAPAN; PATHOLOGY; REFRACTORY ANEMIA WITH EXCESS BLASTS; TREATMENT OUTCOME;

ADULT; ANEMIA, REFRACTORY, WITH EXCESS OF BLASTS; ASIAN CONTINENTAL ANCESTRY GROUP; BLOOD CELL COUNT; BONE MARROW; CYCLOSPORINE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; JAPAN; MYELODYSPLASTIC SYNDROMES; TREATMENT OUTCOME;

EID: 0036551481     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02982046     Document Type: Article

References (11)

1. Biesma DH, van den Tweel JG, Verdonck LF. Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer. 1997;79:1548-1551.
2. Hellstrom-Lindberg E. Treatment of adult myelodysplastic syndromes. Int J Hematol. 1999;70:141-154.
3. Nand S, Godwin JE. Hypoplastic myelodysplastic syndrome. Cancer. 1988;62:958-964.
4. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol. 1998;100:304-309.
5. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51:189-199.
6. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
7. Bennett JM. World Health Organization classification of the acute leukemias and myelodysplastic syndrome. Int J Hematol. 2000;72:131-133.
8. Motoji T, Teramura M, Takahashi M, et al. Successful treatment of refractory anemia with high-dose methylprednisolone. Am J Hematol. 1990;33:8-12.
9. Molldrem JJ, Caples M, Mavroudis D, Plante M, Young NS, Barrett AJ. Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol. 1997;99:699-705.
10. Catalano L, Selleri C, Califano C, et al. Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica. 2000;85:133-138.
11. Litzow MR, Kyle RA. Multiple responses of aplastic anemia to low-dose cyclosporine therapy despite development of a myelodysplastic syndrome. Am J Hematol. 1989;32:226-229.